53645-95-7

Usage

Uses

Used in Chemical Research:
2-Bromo-5-phenyl-1,3,4-thiadiazole is used as a research compound for its unique structural features, contributing to the development of new chemical entities and understanding its reactivity and properties in various chemical reactions.
Used in Medicinal Research:
2-Bromo-5-phenyl-1,3,4-thiadiazole is used as a pharmaceutical candidate for its potential biological activity, particularly for its antimicrobial, anticonvulsant, and anti-inflammatory properties, which can be harnessed in the development of new drugs and therapies.
Used as a Precursor in Organic Synthesis:
Due to the presence of a bromine atom, 2-Bromo-5-phenyl-1,3,4-thiadiazole is used as a precursor in the synthesis of other organic compounds, facilitating the creation of novel molecules with potential applications in various industries.
Used in Pharmaceutical Industry:
2-Bromo-5-phenyl-1,3,4-thiadiazole is used as an active pharmaceutical ingredient or intermediate in the development of new drugs, leveraging its biological properties to address specific medical needs.
Used in Safety and Toxicity Studies:
2-Bromo-5-phenyl-1,3,4-thiadiazole is used in safety and toxicity studies to evaluate its potential risks and side effects, ensuring the safety of its applications in various fields.

InChI:InChI=1/C8H5BrN2S/c9-8-11-10-7(12-8)6-4-2-1-3-5-6/h1-5H

Upstream product

• 24028-40-8 5-phenyl-1,3,4-thiadiazolin-2-one 
• 2002-03-1 2-amino-5-phenyl-1,3,4-thiadiazole 
• 55981-29-8 2,5-dibromo-1,3,4-thiadiazole 
• 98-80-6 phenylboronic acid 
• 100-52-7 benzaldehyde 
• 94794-26-0 (2E)-2-benzylidenehydrazinecarbothioamide 
• 71-43-2 benzene 
• 65-85-0 benzoic acid 
• 312619-47-9 2-amino-5-phenyl-1,3,4-thiadiazole sulfate 

Downstream Products

• 96134-33-7 N,N-diethyl-5-phenyl-1,3,4-thiadiazol-2-amine 
• 57709-35-0 1-methyl-4-(5-phenyl-[1,3,4]thiadiazol-2-yl)-piperazine 
• 28873-45-2 2-phenyl-5H-1,3,4-thiadiazolo<2,3-b>quinazolin-5-one 
• 13229-03-3 2-hydrazino-5-phenyl-1,3,4-thiadiazole 
• 85730-47-8 diethyl 2-(5-phenyl-1,3,4-thiadiazol-2-yl)malonate 
• 1456-67-3 2-(4'-methoxyphenyl)-5-phenyl-1,3,4-thiadiazole 
• 85730-57-0 C-(5-Phenyl-[1,3,4]thiadiazol-2-yl)-methylamine 
• 85730-46-7 2-(5-phenyl-1,3,4-thiadiazol-2-yl)acetic acid 
• 18070-82-1 2-ethoxycarbonylmethyl-5-phenyl-1,3,4-thiadiazole 
• 85730-49-0 ethyl α-amino-2-phenyl-1,3,4-thiadiazol-5-ylacetate 
• 85730-48-9 ethyl α-oximino-2-phenyl-1,3,4-thiadiazol-5-ylacetate 
• 85730-58-1 (5-Phenyl-[1,3,4]thiadiazol-2-ylmethyl)-carbamic acid 2,2,2-trichloro-ethyl ester 
• 85730-50-3 (5-Phenyl-[1,3,4]thiadiazol-2-yl)-(2,2,2-trichloro-ethoxycarbonylamino)-acetic acid ethyl ester 
• 170573-28-1 2-(-6-Decyloxy-2-fluoropyrid-3-yl)-5-phenyl-1,3,4-thiadiazole 

Relevant academic research and scientific papers

COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME

The present specification provides a compound represented by chemical formula 1 and an organic light emitting device including the same. The compound may improve lifespan characteristics of the organic light emitting device.

Novel C7-substituted coumarins as selective monoamine oxidase inhibitors: Discovery, synthesis and theoretical simulation

There is a continued need to develop new selective human monoamine oxidase (hMAO) inhibitors that could be beneficial for the treatment of neurological diseases. However, hMAOs are closely related with high sequence identity and structural similarity, which hinders the development of selective MAO inhibitors. “Three-Dimensional Biologically Relevant Spectrum (BRS-3D)” method developed by our group has demonstrated its effectiveness in subtype selectivity studies of receptor and enzyme ligands. Here, we report a series of novel C7-substituted coumarins, either synthesized or commercially purchased, which were identified as selective hMAO inhibitors. Most of the compounds demonstrated strong activities with IC50 values (half-inhibitory concentration) ranging from sub-micromolar to nanomolar. Compounds, FR1 and SP1, were identified as the most selective hMAO-A inhibitors, with IC50 values of 1.5 nM (selectivity index (SI) 50 of 18 nM and 15 nM (SI > 2.74 and SI > 2.82). Docking calculations and molecular dynamic simulations were performed to elucidate the selectivity preference and SAR profiles.

Bicyclic alkaloid compound, preparation method and applications thereof

The present invention relates to a bicyclic alkaloid compound, or a tautomer, a stereoisomer, a racemate, the non-equal mixture of enantiomers, a geometric isomer, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, and a pharmaceutical composition containing the compound. The invention further discloses uses of the compounds and the pharmaceutical composition thereof as drugs, especially as anti-inflammatory drugs and anti-fibrotic drugs.

AZAADAMANTANE FORMATE ESTER AND PROCESS FOR PREPARING AZAADAMANTANE DERIVATIVES

A compound, (4s)-1-azaadamantane-4yl formate ester, is described. In addition, a process is described for preparing (4s)-1-azaadamantane-4yl formate ester, aminothiadiazole-phenyl phosphate salt, bromothiadizole-phenyl or (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.13,7]-decane dihydrogen citrate. Furthermore, a process is described, comprising step of hydrolyzing (4s)-1-azaadamantane-4yl formate ester to form (4s)-1-azaadamantan-4-ol HBr salt.

BIARYL SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY MODULATORS

The invention relates to biaryl substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Substituted diazabicycloalkane derivatives

Compounds of formula (I) [in-line-formulae]Z-Ar1—Ar2??(I) [/in-line-formulae] wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

Substituted diazabicycloakane derivatives

Compounds of formula (I) Z-Ar1—Ar2??(I) wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from an unsubstituted or substituted 5-membered heteroaryl ring; an unsubstituted or substituted 6-membered heteroaryl ring; 3,4-(methylenedioxy)phenyl; and phenyl substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

SPIRO ′1-AZABICYCLO ′2.2.2!OCTAN-3,5′-OXAZOLIDIN -2′-ONE! DERIVATIVES WITH AFFINITY TO THE ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR

Compounds of formula (I) and pharmaceutically-acceptable salts thereof, wherein Arl, A and Ar2 are as defined in the specification, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare them, uses of them as medicaments for therapy, uses of them in the manufacture of medicaments and uses of them for diagnostic and analytic purposes.

General facile synthesis of 2,5-diarylheteropentalenes

Palladium-catalyzed cross-coupling reactions of various heteropentalene derivatives were systematically studied. A general three-step synthesis of 2,5-diarylheteropentalenes involving two Suzuki or Negishi couplings and a regiospecific bromination was developed. Nonsymmetrical 2,5-diaryl-furans, thiophenes, pyrroles, 1,3-thiazoles, 1,3-oxazoles, 1,3,4-thiadiazoles, and 1,3,4-oxadiazoles were prepared in 31-67% isolated yield (three steps).

Thiadiazole derivatives, process for their preparation, and their use as precursors for the production of liquid crystals

Thiadiazole derivatives of the formula (I) in which the symbols and indices have the following meanings: X is Cl, Br or I; B is 1,3,4-thiadiazole-2,5-diyl; A1, A2 and A3 are identical or different and are substituted or un